Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Sep 6;18(1):139.
doi: 10.1186/s12883-018-1143-z.

Rheumatoid meningitis presenting with a stroke-like attack treated with recombinant tissue plasminogen activator: a case presentation

Affiliations
Case Reports

Rheumatoid meningitis presenting with a stroke-like attack treated with recombinant tissue plasminogen activator: a case presentation

Masashi Akamatsu et al. BMC Neurol. .

Abstract

Background: Rheumatoid meningitis presenting with a stroke-like attack (RMSA) is a rare manifestation of rheumatoid arthritis (RA). When the patients arrive within the time-window for recombinant tissue plasminogen activator (rt-PA) infusion therapy, no diagnostic protocol has been established.

Case presentation: A 55-year-old woman was brought by ambulance to our hospital with complaints of sudden-onset dysarthria and left arm numbness. The National Institutes of Health Stroke Scale (NIHSS) score was 5, and the Alberta Stroke Program Early CT Score was 8. She was diagnosed with acute embolic stroke. At 4 h, 6 min after onset, intravenous administration of rt-PA (alteplase, 0.6 mg/kg) was started. Her neurological deficits improved rapidly, and her NIHSS score was 1. Brain MRI was then performed. There was no hemorrhagic transformation, but the MRI findings were not compatible with ischemic stroke. She had a past history of RA diagnosed 6 months earlier, and she had been treated with methotrexate (10 mg daily). She was diagnosed with RMSA, and continuous infusion of methylprednisolone 1000 mg daily was started for 3 days. The high signal intensity on the FLAIR image disappeared.

Conclusion: CT-based decision-making for rt-PA injection is reasonable, but MRI is needed for the early diagnosis of RMSA. In this case, it is particularly important that neither adverse events nor bleeding complications were observed, suggesting the safety of CT-based thrombolytic therapy in RMSA.

Keywords: Recombinant tissue plasminogen activator (rt-PA); Rheumatoid meningitis; Stroke mimics.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written, informed consent was obtained from the patient for the publication of this case report and accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Brain CT images (a, b) do not show a hypodense area at admission, but equivocal findings of effacement in the right temporoparietal region (ASPECT score, 8). CT angiography (c) shows no vascular occlusion or stenosis. CT = computerized tomography, ASPECTS = Alberta Stroke Program Early CT Score
Fig. 2
Fig. 2
MRI findings at day 1. DWI (a) demonstrates a linear high-intensity lesion in the right frontotemporal cortex. Reduced ADC of this lesion is seen on the ADC map (b), and this cortical lesion appears as a high-intensity lesion on the FLAIR image (c). MRI = magnetic resonance imaging, DWI = diffusion-weighted imaging, ADC = apparent diffusion coefficient, FLAIR = fluid attenuated inversion recovery
Fig. 3
Fig. 3
MRI images at day 3. The abnormal findings at day 1 have disappeared on DWI (a) and the ADC image (b), but the high-intensity area remains on the FLAIR image (c) at day 3. There is no definite enhancement of the lesion on gadolinium-enhanced T1-weighted imaging (d). MRI = magnetic resonance imaging, DWI = diffusion-weighted imaging, ADC = apparent diffusion coefficient, FLAIR = fluid attenuated inversion recovery

Similar articles

Cited by

References

    1. Bougea A, Anagnostou E, Konstantinos G, et al. A systematic review of peripheral and central nervous system involvement of rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome, and associated immunological profiles. Int J Chronic Dis. 2015;2015:910352. - PMC - PubMed
    1. Manabe Y, Narai H, Warita H, et al. Rheumatoid factor positive hypertrophic cranial pachymeningitis in association with hypopituitarism and multiple cranial nerve palsies. Intern Med. 2001;40:964–967. doi: 10.2169/internalmedicine.40.964. - DOI - PubMed
    1. Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology. 2007;68:1079–1080. doi: 10.1212/01.wnl.0000257824.72457.91. - DOI - PubMed
    1. Magaki S, Chang E, Hammond RR, et al. Two cases of rheumatoid meningitis. Neuropathology. 2016;36:93–102. doi: 10.1111/neup.12238. - DOI - PubMed
    1. Kern R, Nagayama M, Toyoda K, et al. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis. 2013;35:402–418. doi: 10.1159/000351753. - DOI - PubMed

Publication types

MeSH terms